Pharvaris (PHVS) Stock Forecast, Price Target & Predictions
PHVS Stock Forecast
Pharvaris stock forecast is as follows: an average price target of $39.67 (represents a 65.78% upside from PHVS’s last price of $23.93) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
PHVS Price Target
The average price target for Pharvaris (PHVS) is $39.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $27.00. This represents a potential 65.78% upside from PHVS's last price of $23.93.
PHVS Analyst Ratings
According to 4 Wall Street analysts, Pharvaris's rating consensus is 'Buy'. The analyst rating breakdown for PHVS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pharvaris Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Justin Kim | Oppenheimer | $42.00 | $19.73 | 112.87% | 75.51% |
| Apr 11, 2024 | Jonathan Wolleben | JMP Securities | $50.00 | $22.27 | 124.52% | 108.94% |
| Sep 25, 2023 | Laura Chico | Wedbush | $27.00 | $20.67 | 30.62% | 12.83% |
| Jan 11, 2023 | - | JMP Securities | $23.00 | $10.32 | 122.87% | -3.89% |
| Dec 09, 2022 | - | JMP Securities | $22.00 | $11.46 | 91.97% | -8.07% |
The latest Pharvaris stock forecast, released on Oct 14, 2024 by Justin Kim from Oppenheimer, set a price target of $42.00, which represents a 112.87% increase from the stock price at the time of the forecast ($19.73), and a 75.51% increase from PHVS last price ($23.93).
Pharvaris Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $42.00 | $42.00 | $46.00 |
| Last Closing Price | $23.93 | $23.93 | $23.93 |
| Upside/Downside | 75.51% | 75.51% | 92.23% |
In the current month, the average price target of Pharvaris stock is $42.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 75.51% increase as opposed to Pharvaris's last price of $23.93. This month's average price target is down 0.00% compared to last quarter, and down -8.70% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 06, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 15, 2023 | Morgan Stanley | - | Overweight | Upgrade |
| Feb 03, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Jan 11, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Dec 09, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
Pharvaris's last stock rating was published by Oppenheimer on Oct 14, 2024. The company gave PHVS a "Outperform" rating, the same as its previous rate.
Pharvaris Financial Forecast
Pharvaris Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $7.85M | $2.45M | - | - | - | - | - | - | - | - | - |
| High Forecast | $7.85M | $2.45M | - | - | - | - | - | - | - | - | - |
| Low Forecast | $7.85M | $2.45M | - | - | - | - | - | - | - | - | - |
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Pharvaris's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PHVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Pharvaris EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict PHVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pharvaris's previous annual EBITDA (undefined) of $NaN.
Pharvaris Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-52.40M | $-54.51M | $-51.87M | $-39.17M | $-41.95M | $-40.32M | $-39.24M | $-37.52M | $-38.75M | $-35.56M | $-31.88M |
| High Forecast | $-52.40M | $-54.51M | $-51.87M | $-39.17M | $-41.95M | $-40.32M | $-39.24M | $-37.52M | $-38.75M | $-32.86M | $-31.88M |
| Low Forecast | $-52.40M | $-54.51M | $-51.87M | $-39.17M | $-41.95M | $-40.32M | $-39.24M | $-37.52M | $-38.75M | $-39.87M | $-31.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Pharvaris's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PHVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Pharvaris SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Pharvaris's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PHVS last annual SG&A of $NaN (undefined).
Pharvaris EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.97 | $-1.01 | $-0.96 | $-0.73 | $-0.78 | $-0.75 | $-0.73 | $-0.70 | $-0.72 | $-0.66 | $-0.59 |
| High Forecast | $-0.97 | $-1.01 | $-0.96 | $-0.73 | $-0.78 | $-0.75 | $-0.73 | $-0.70 | $-0.72 | $-0.61 | $-0.59 |
| Low Forecast | $-0.97 | $-1.01 | $-0.96 | $-0.73 | $-0.78 | $-0.75 | $-0.73 | $-0.70 | $-0.72 | $-0.74 | $-0.59 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Pharvaris's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PHVS previous annual EPS of $NaN (undefined).
Pharvaris Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| HOWL | Werewolf Therapeutics | $2.26 | $12.00 | 430.97% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
| JANX | Janux Therapeutics | $55.87 | $61.20 | 9.54% | Buy |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
PHVS Forecast FAQ
Is Pharvaris a good buy?
Yes, according to 4 Wall Street analysts, Pharvaris (PHVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PHVS's total ratings.
What is PHVS's price target?
Pharvaris (PHVS) average price target is $39.67 with a range of $27 to $50, implying a 65.78% from its last price of $23.93. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Pharvaris stock go up soon?
According to Wall Street analysts' prediction for PHVS stock, the company can go up by 65.78% (from the last price of $23.93 to the average price target of $39.67), up by 108.94% based on the highest stock price target, and up by 12.83% based on the lowest stock price target.
Can Pharvaris stock reach $40?
PHVS's highest twelve months analyst stock price target of $50 supports the claim that Pharvaris can reach $40 in the near future.
What is Pharvaris's current price target trend?
1 Wall Street analyst forecast a $42 price target for Pharvaris (PHVS) this month, up 75.51% from its last price of $23.93. Compared to the last 3 and 12 months, the average price target increased by 75.51% and increased by 92.23%, respectively.
What are Pharvaris's analysts' financial forecasts?
Pharvaris's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-159M (high $-159M, low $-159M), average SG&A $0 (high $0, low $0), and average EPS is $-2.948 (high $-2.948, low $-2.948). PHVS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $10.3M (high $10.3M, low $10.3M), average EBITDA is $0 (high $0, low $0), average net income is $-198M (high $-198M, low $-198M), average SG&A $0 (high $0, low $0), and average EPS is $-3.67 (high $-3.67, low $-3.67).